In the last few days there have been encouraging "preliminary" reports that IL-6 inhibition by either tocilizumab or sarilumab may be efficacious in patients with severe coronavirus infections.
Sarilumab (Kevzara)
JAMA Open Network reports an interim analysis of the Brazilian CloroCovid-19 trial showing thta higher doses of chloroquine (CQ) in the treatment of severe COVID-19 was associated with QTc interval prolongation and increased mortality.
Dr Jack Cush reviews the news, journal reports, twitter feed and COVID developments from the past week on RheumNow.com
A pre-proof letter to the editor in the Journal of Allergy and Clinical Immunology presents a series of patients with immunoglobulin deficiency disorders and how they differentially responded when infected with the coronavirus.
A National Institutes of Health (NIH) expert panel has developed consensus treatment guidelines for the management of coronavirus (COVID-19). To date no drug has been proven to be safe and effective for treating COVID-19.
Dr. Alvin Wells gives a primer on Telerheumatology and Telemedicine in the era of COVID-19.
Early reports on the COVID-19 pandemic allude to a cytokine storm or hyper-inflammation, especially in patients who succumbed to the illness.
Journal of Experimental Medicine has published a paper from a consortium of researchers at Cold Spring Harbor Laboratory, the Feinstein Institutes for Medical Research, and the Research Institute of the McGill University Health Centre (RI-MUHC) on the potential of neutrophil extracellula
Dr. Jack Cush reviews the news, journal articles and new ACR COVID-19 guidelines from the past week on RheumNow.com.
“So far, we’ve been wrong about everything” claimed a U.S. governor during a TV interview.
The presentations of the COVID-19 infection have been clearly chronicled with the worrisome onset of sore throat, dry cough, loss of smell and taste with fevers, myalgias, fatigue and the worrisome progression of pulmonary involvement in a minority. Lab findings may include a leukocytosis,
On April 11th, the ACR Board of Directors approved a COVID-19 guidance document written by an ACR task force charged with updating and clarifying recommendations for rheumatologists and rheumatic disease patient management during the current COVID-19 crisis.
TheDaoIndex @KDAO2011 ( View Tweet )
TheDaoIndex @KDAO2011 ( View Tweet )
TheDaoIndex @KDAO2011 ( View Tweet )
swethaann23 @swethaann23 ( View Tweet )
